A Differential Approach to the Treatment of Acute Psychosis Due to Consumption of Synthetic Cannabinoids

  • Z. I. Kekelidze
  • T. V. KlimenkoEmail author
  • A. A. Kozlov
  • S. M. Shakhova

Objectives. To develop a differential approach to the treatment of acute psychosis induced by synthetic cannabinoids. Materials and methods. A total of 43 patients aged 18–45 years with acute psychosis due to consumption of synthetic cannabinoids were studied. Clinical psychology, psychometric, and laboratory methods were used, along with statistical analysis. Results and conclusions. Inclusion of neuroleptic agents into complex therapy increased treatment efficacy. Selection of neuroleptics requires not only the psychopathological structure of the psychosis, but also the severity of psychosis-associated somatoneurological disorders to be considered.


new psychoactive substances synthetic cannabinoids spice psychoses 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    World Narcotics Report,, acc. May 10, 2017
  2. 2.
    Drug Facts: K2/Spice (Synthetic Marijuana”), National Institute on Drug Abuse,, acc. May 10, 2017
  3. 3.
    European Monitoring Centre for Drugs and Drug Addiction, Synthetic Cannabinoids and “Spice” Profile,, acc. May 10, 2017
  4. 4.
    N. A. Bokhan and G. Yu. Selivanov, “Clinical typology of psychological disorders in consumers of synthetic cannabinoids (spices),” Sib. Vestn. Psikhiatr. Narkol., 4, No. 89, 18–23 (2015).Google Scholar
  5. 5.
    L. Fattore, “Synthetic cannabinoids – further evidence supporting the relationship between cannabinoids and psychosis,” Biol. Psychiatry, 79, 539–548 (2016).CrossRefGoogle Scholar
  6. 6.
    I. V. Bondar’, A. V. Nadezhdin, Yu. E. Vyazovichenko, et al., “Current relevance of the challenge of smoking mixtures (spices),” in: Proc. All-Russ. Sci. Appl. Conf. Countering the Illegal Circulation of Narcotics, Psychotropics, and Their Analogs and Precursors in Contemporary Russia: Criminal Legal and Criminological Aspects, I. I. Batyrshina (ed.), Russian Federal Drug Trafficking Monitoring Service Research Institute, Moscow (2015), pp. 27–32.Google Scholar
  7. 7.
    S. A. Savchuk, “Detection of synthetic cannabinoids, narcotics, psychoactive substances and their metabolites in urine, hair, and nails by liquid chromatography and mass spectrometry. An information letter,” Narkologiya, 8, 42–52 (2014).Google Scholar
  8. 8.
    T. V. Klimenko, S. M. Shakhova, and A. A. Kozlov, “Psychotic disorders due to consumption of synthetic cannabinoids (spices),” Sib. Vestn. Psikhiatr. Narkol., 2, No. 95, 25–29 (2017).Google Scholar
  9. 9.
    S. Bazire, “Risperidone in schizophrenia,” Brit. J. Psychiatry, 168, No. 1, 128 (1996),
  10. 10.
    Yu. B. Belousov, V. S. Moiseev, and V. K. Lepakhin, Clinical Pharmacology and Pharmacotherapy. Guidelines for Doctors, Universum Publishing (1997), 2nd ed.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Z. I. Kekelidze
    • 1
  • T. V. Klimenko
    • 1
    • 2
    Email author
  • A. A. Kozlov
    • 1
  • S. M. Shakhova
    • 1
    • 3
  1. 1.Serbskii Federal Medical Research Center for Psychiatry and NarcologyMoscowRussia
  2. 2.All-Russia State University of JusticeMoscowRussia
  3. 3.Sechenov First Moscow Medical University (Sechenov University)Russian Ministry of HealthMoscowRussia

Personalised recommendations